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ABSTRACT 
Objective: The aim of this study was to develop a liquisolid formulation of propranolol hydrochloride to obtain an improved sustained release 
profile by varying the ratio of liquid vehicles. 
Methods: In this study, propranolol hydrochloride (PPH) was dispersed in the combination of propylene glycol and polysorbate 80, as the liquid 
vehicles, with different ratios. Eudragit® RL and Aerosil®
Results: The results show that all formulations performed dry and free-flowing granules containing PPH in the range of 7-9%. Furthermore, all the 
prepared formulations were able to sustain the drug release for a total of 8 h in two different dissolution media, namely simulated gastric fluid and 
simulated intestinal fluid. F4 containing propylene glycol and polysorbate 80 (1:2) possessed the lowest drug release rate. It was also obtained that 
F1 and F3 followed first-order kinetics while F2, F4, and F5 complied with the Higuchi model.  
 were used as carrier and coating materials, respectively, to produce a dry and free-flowing 
powder. In addition, HPMC was used to amplify the retardation effect. The prepared formulations were evaluated for its physicochemical 
properties, including loss on drying, flow rate, angle of repose calculation, drug content analysis, FT-IR spectroscopy, as well as dissolution studies. 
The obtained dissolution profiles were subsequently fitted to the mathematical model in order to determine the drug kinetics.  
Conclusion: Overall, there was no difference in all the dissolution profiles based on the calculation of the difference and similarities factor. 
Keywords: Liquisolid granules, Propranolol hydrochloride, Sustained release 
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INTRODUCTION 
During the last decades, conventional dosage forms are rapidly 
replaced by novel drug delivery systems. Sustained release dosage 
forms have become one of the most favourable in modern 
therapeutics [1]. Sustained release drug delivery system is an 
alternative to maintain therapeutic dose in the systemic after a 
single application. This can be a solution to optimize the efficacy and 
safety of the treatment, also reduce the frequency of drug 
consumption resulting in improving patient compliance [2]. The 
candidate drug that is able to be formulated into sustained release 
dosage form must possess some of the criteria, including having a 
short half-life, high-frequent usage of drugs, and low dose drugs, 
which are preferred [3]. There are several methods that can be 
utilised to sustain the drug release, including the incorporation of 
drugs into hydrophobic materials, coating with swelling polymers, 
and encapsulating the drug molecule with certain polymers [4]. 
Liquisolid technology is a novel and promising method to produce a free-
flowing and compressible dry powder using simple physical mixing of 
carrier and coating materials incorporated into a non-volatile liquid 
containing drugs [5]. The type of liquid used in this system is mainly non-
volatile liquid, water-miscible with high boiling temperatures, such as 
propylene glycol, polyethylene glycols, glycerine, or polysorbate [5]. The 
drug powder is incorporated in the liquid resulting in liquid medication, 
either a drug solution or a drug suspension. After the carrier powder is 
saturated with the liquid medication, a liquid layer formed on the 
particle surface is adsorbed by the coating material. Consequently, a dry, 
free-flowing, and compressible powder is obtained [6]. This technology 
is initially used in the purpose of improving drug solubility of poorly 
water-soluble drugs by using water-soluble polymer [7–9]. However, 
this method has been developed and the same principle was utilised to 
prepare sustained release formulation using hydrophobic polymers [5, 




Fig. 1: Schematic representation of liquisolid system 
 
Propranolol, in the form of hydrochloride salt, is a suitable drug for 
sustained release formulation. It is one of the β-blocker anti-
hypertension drugs with a dose of 40 mg twice daily [11]. 
Propranolol is classified in the Biopharmaceutical Classification 
System (BCS) Class I with high solubility and high permeability 
which lead to fast elimination out the body. Additionally, it has low 
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oral bioavailability that is only 25% reached the systemic circulation 
after a single administration. This results in the short half-life of 
propranolol which is 3 to 6 h [2, 12]. Consequently, the frequent 
dose is needed to maintain the therapeutic dose and efficacy of 
treatment. Nowadays, propranolol is available as immediate and 
controlled release oral dosage forms. Previously, Javadzadeh, et al. 
(2008) has reported the successful approach of propranolol 
hydrochloride formulation using liquisolid technique for sustained 
release delivery. However, in the previous studies, only one type of 
non-volatile liquid was used in each formulation [2]. Therefore, in 
the present work, the combination of two types of non-volatile 
liquid, namely propylene glycol and polysorbate 80, in certain ratios 
were used in the liquisolid formulations, which were further 
evaluated on the physicochemical properties and dissolution profile.  
MATERIALS AND METHODS 
Materials 
Propranolol HCl (PPH) was obtained from PT. Kimia Farma (Jakarta, 
Indonesia), Eudragit® RL, Aerosil®
Application of mathematical model for the design of liquisolid 
granules 
, and hydroxypropyl 
methylcellulose (HPMC) were purchased from CV. Asian (Jakarta, 
Indonesia), polysorbate 80 was obtained from CV. Sentana 
(Makassar, Indonesia). All other materials were of analytical grade. 
A mathematical model was introduced by Spireas et al. to design the 
formulation of liquisolid system [6, 13]. In the present work, propylene 
glycol and polysorbate 80 were used as liquid vehicles, Eudragit® RL 
and Aerosil®
The excipients ratio (R) of powder is defined in the following 
equation:  
 were used as the carrier and coating materials, 
respectively. Additionally, HPMC was used as a retardant agent. The 
ratio of the carrier and coating materials, also known as the excipients 
ratio (R), was 20. It has been acknowledged that a powder can only 
retain a certain amount of liquid, termed as liquid load factor, while 
still meet the acceptance flow and compression properties.  
R = Q
q
 ……. Equation (1) 
Where Q is the amount of the carrier material and q is the amount of 
the coating material. 




 ……. Equation (2) 
 is the ratio between the weight of liquid 
medication (W) and the carrier material (Q) presents in the system, 
as written in the equation below:  
Formulation of liquisolid granules of propranolol HCl 
The liquisolid granules were prepared by firstly dispersing PPH in the 
liquid carrier, as illustrated in fig. 2. The carrier and coating materials, 
Eudragit® RL and Aerosil®
 
, respectively, were subsequently 
incorporated into drug suspension resulting in a homogenous powder 
mixture. Furthermore, HPMC solution as the retardant agent was 
added to form a plastic mass. Finally, the mass was sieved using mesh 
no. 14 in order to obtain fine granules. The drying process of granules 
was performed at 50 °C for 3 d before being evaluated. The 
formulations of liquisolid granules of PPH were presented in table 1. 
 
Fig. 2: Illustration of the steps in the formulation of PPH liquisolid 
 
Table 1: Formulation of PPH liquisolid granules 
 F1 F2 F3 F4 F5 
PPH (g) 1.2 1.2 1.2 1.2 1.2 
Eudragit® 6.0  RL (g) 6.0 6.0 6.0 6.0 
Aerosil® 0.3  (g) 0.3 0.3 0.3 0.3 
Propylene glycol (g) 3.0 2.0 1.5 1.0 - 
Polysorbate 80 (g) - 1.0 1.5 2.0 3.0 
HPMC 1% (ml) 4.0 4.0 4.0 4.0 4.0 
All formulations contained liquid load factor = 0.7 and excipient ratio = 20 
 
Physicochemical evaluation  
Loss on drying (LOD) evaluation 
LOD was used to determine the percentage of water contained in the 
granules by weighing the granules before and after the drying 
process. LOD was calculated using Equation (3): 
LOD (%) = wet granules weight−dry granules weight
wet granules weight
 ……. Equation (3) 
Flow rate and angle of repose evaluation 
As liquisolid technology is used to prepare a free-flowing powder, the 
flow rate and angle of repose were considerably important to be 
evaluated to determine the flowing properties of the granules. A flow 
rate evaluation was carried out by counting the flowing time of 5 g of 
granules from the determined height. Moreover, the angle of repose 
evaluation by measuring the angle of the formed pile of granules. Both 
evaluations were calculated using Equation (4) and (5) [14]: 
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Flow rate v = m
t
 …… Equation (4) 
Angle of repose θ = tan−1 �2h
d
� ……. Equation (5) 
Where v is the flow rate, m is the mass of granules, t is the flowing 
time of granules, � is the angle of repose, h is the height of the pile, 
and d is the length of the pile base. 
Fourier transform infrared (FT-IR) spectroscopy 
FT-IR spectroscopy was conducted in order to detect any 
interactions between drugs and excipients. The IR spectra of the 
samples were recorded between 4500-250 cm-1 using 32 scans with 
a resolution of 4.0 cm-1
Drug content analysis 
 at room temperature (20 °C). 
An amount of 10 mg of granules was dissolved in simulated gastric 
fluid up to 10 ml before being sonicated for 10 min. The solution was 
subsequently filtered, and 1.25 ml of the filtrate was diluted with 
simulated gastric fluid up to 5 ml. The final solution was measured 
using a spectrophotometer UV-Visible at 290 nm. 
Dissolution studies 
An amount of granules, equivalent to 40 mg PPH, was tested using 
dissolution apparatus type 1 (rotating basket). The dissolution test was 
performed in two different dissolution media, 900 ml of simulated 
gastric fluid and 900 ml of simulated intestinal fluid. All the experiments 
were performed at 50 rpm at 37 °C. An aliquot of 5 ml was taken using 
millipore after 30 and 60 min in a simulated gastric fluid medium and 
after 1, 2, 3, 4, 5, 6 and 7 h in simulated intestinal fluid. Each sample was 
diluted using the suitable dissolution medium up to 10 ml. The sample 
taken was replaced with fresh dissolution medium. The amount of PPH 
in the sample was measured using a spectrophotometer UV-Visible at 
290 nm. All experiments were conducted in triplicates. 
Drug release kinetics determination 
In order to describe the dissolution profiles of liquisolid granules, 
the data obtained were analysed using the mathematical equation of 
each kinetic model [15–18]: 
Zero order: Ct = Co + kot ……. Equation (6) 
First order: ln Ct = ln Co + k1t     ….. Equation (7) 
Higuchi model: Ct = kH√t  …….. Equation (8) 
Hixson-Crowell model: Ct
1/3 = C0
1/3 + kHCt     Equation (9) 
Where Ct is the concentration of drug dissolved in time t, Co is the 
initial concentration of the drug, ko is the zero order release 
constant, k1 is the first order release constant, kH is the Higuchi 
model constant, and kHC is the Hixson-Crowell model constant. The 
value of correlation coefficient (r2) was used to determine the best-
fitted release model of each formulation.  
Data analysis 
The difference (f1) and similarity (f2) factors were calculated in 
order to compare the release profiles of each liquisolid formulation. 
The difference factor (f1) was used to measure the percentage of 
difference and percent error between two dissolution profiles over 
all time points. Besides, the similarity factor (f2) is a logarithmic 
square-root transformation of differences between two formulations 
referred as the test and the reference. Equation (10) and (11) were 
used to calculate f1 and f2
Where n is the number of sampling time, R
, respectively [19]. 
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t  is the reference 
dissolution percentage at time t, and Tt  is the test dissolution 
percentage at time t. Two dissolution profiles are considered similar 
if the value of f1 is lower than 15 (in the range of 0-15) and the value 
of f2
RESULTS AND DISCUSSION 
 is more than 50 (in the range of 50-100). 
Formulation of liquisolid granules of propranolol HCl 
Liquisolid method was chosen as the most suitable method to 
prepare sustained-release granules for oral delivery due to its 
simplicity in process and availability of the materials [20]. In this 
research, PPH was selected as the drug model because of its good 
solubility and good permeability. This caused PPH to become the 
most suitable candidate for prolonged-release delivery. Besides, its 
massive use as an antihypertension drug was another consideration 
for better improvement in efficacy and patient compliance [21].  
Briefly, the process involved in the preparation of liquisolid granules 
was similar to wet granulation method in tablet preparation due to 
the incorporation of liquid, in this case was HPMC 1% solution, 
resulting in forming a plastic mass which was further sieved into 
granules. Eudragit® RL is one of the polymethacrylates that is 
commonly used as a water-insoluble film coating for sustained 
release delivery [22]. In the liquisolid system, the physicochemical 
properties of Eudragit® RL met the requirement as carrier material, 
to absorb the drug liquid and modify the properties of PPH from 
water-soluble to water-insoluble. Coating materials with high 
adsorptive properties and large surface area such as Aerosil®
Physicochemical evaluation  
 were 
able to produce free-flowing dry liquisolid powder. The addition of 
HPMC increased the retardation effect of this system [23].  
Loss on drying (LOD) evaluation 
LOD percentage was calculated to determine the amount of water loss in 
the drying process. This parameter indicated the varied concentration of 
propranolol in the system, which was subsequently calculated in the 
drug content evaluation. The amount of water loss in the drying process 
was more than presented in the designed formulations. This might be 
caused by the hygroscopicity of both propylene glycol and polysorbate 
80 [22]. Hence, the drying process was considerably important to ensure 
the granules was dry prior to evaluation. 
  
Table 2: The results of LOD, flow rate, and angle of repose evaluations 
 %LOD Flow rate (g/s) Angle of repose ( °) 
F1 46.88 1.09 24.52 
F2 42.14 1.51 28.85 
F3 38.73 1.10 30.20 
F4 35.71 2.07 26.52 
F5 26.15 4.19 20.96 
 
Flow rate and angle of repose evaluation 
The flow properties of powder or granules were essential to be 
determined because it was going to be compressed into tablets or 
filled in capsules. This evaluation was performed by measuring the 
flow rate. The method used in this study was simple and easy, yet 
adequate by measuring the time taken of an amount of granules to 
flow from a tunnel at a certain height to a flat surface. The higher 
flow rate showed better flow properties. Furthermore, angle of 
repose can be another parameter to evaluate the granules flow 
properties. Granules with the angle of repose of less than 30 °C 
indicated very good flow properties [24]. From table 2, it can be seen 
that all formulations met the requirements, which means the 
granules prepared are free-flowing.  
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Fig. 3: FTIR spectra of (a) propranolol hydrochloride, (b) F1, (c) F2, (d) F3, (e) F4, and (f) F5, respectively 
 
FT-IR spectroscopy 
Interaction between drug and excipients was observed using FT-IR 
spectroscopy. The specific peaks detected represented specific chemical 
bonds in the drug or mixture. Based on its chemical structure, PPH has 
several typical peaks as can be seen in fig. 3. Two peaks appeared at 
3321.42 and 3280.92 cm-1 represented secondary amine and hydroxyl 
groups, respectively. Additionally, the chemical bond of C-H as methyl 
asymmetric group appeared at 2966.52 cm-1 and the absorption of 
aromatic ring band was at 1589.34 cm-1. The other chemical groups, 
including aryl alkyl ether and C-H bond in the aromatic ring was 
observed at 1267.23 and 796.6 cm-1
Drug content analysis 
, respectively [25, 26]. All these 
peaks were also observed in the spectra of all liquisolid formulations 
without major shifting. Therefore, it was confirmed that no chemical 
interaction was found between PPH and other excipients. This means 
that there is no change in the chemical structure of PPH, which indicated 
efficacy in the therapeutic effect of PPH. 
In the liquisolid system, the drug is entrapped and surrounded by the 
hydrophobic polymer. Therefore, the sonication process was important 
to ensure all the drug in the granules was dissolved prior to 
measurement. The drug content analysis was carried out in order to fig. 
out the amount of PPH in the liquisolid system. It can be seen that the 
percentage of PPH in the granules was in the range between 7-9%. The 
varied concentration obtained might be caused by the different 
percentage on loss on drying process. However, as the results of this 
evaluation were used as the basis to calculate the drug released in the in 
vitro release studies, the varied results were not highly concerned. 
 
Table 3: Percentage of the drug content of PPH liquisolid 
formulations (mean±SD, n=3) 







In this study, the dissolution studies were conducted in two different 
dissolution media, namely simulated gastric fluid and simulated 
intestinal fluid. It is important to note that the liquisolid system prepared 
in this research was not designed for mucoadhesive or floating system. 
Accordingly, the use of two dissolution media aimed to represent the 
gastric and intestinal, where the drug was expected to release.  
Overall, the results show that all formulations were able to sustain 
until a total of 8 h. This indicated that the presence of Eudragit®
After 1 hour, there was almost no major difference in the percentage of 
drug released of all formulation. However, it can be clearly seen in fig. 
3, F4 was able to provide a more sustained release of PPH compared to 
other formulations at the seventh hour. Interestingly, F5 showed the 
same percentage as F4 at the last time point. This indicated that the 
combination of liquid carrier and the pH of the dissolution media 
played an important role in the dissolution studies. It was reported 
that the presence of liquid vehicle acting as a plasticizer was able to 
decrease the glass transition temperature of Eudragit
 RL 
as a hydrophobic polymer was able to completely to coat the drug 
molecule resulting in prolonged drug release [8]. Moreover, the 
swelling properties of HPMC was able to form a gel barrier that 
controlled the release of PPH [27,28]. Specifically, all the liquisolid 
formulations released less than 50% after 1hour in the simulated 
gastric fluid, with the lowest released percentage was given by F4. In 
contrast, F5 provided the highest amount of PPH released, 
47.13±0.35% after 60 min in the first media. Furthermore, the trend 
of results obtained in the simulated intestinal fluid was slightly 
similar to those in the simulated gastric fluid.  
® RL, resulting in 
retardation effect of liquisolid granules [5, 22]. By varying the ratio of 
liquid vehicle, it was obtained that the liquisolid system containing 
propylene glycol and polysorbate 80 with the ratio of 1:2 provided the 
least dissolution release rate. As reported in the previous studies, the 
solubility of the drug in the liquid carrier also affected the release of 
drug [29]. The solubility of PPH in propylene glycol was higher than in 
polysorbate 80, which lead to the more undissolved drug in the liquid 
carrier [2]. This subsequently increased the retardation effect in the 
liquisolid granules.  
f 
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Based on the difference and similarity factors calculation, as shown 
in table 4, the dissolution profiles of all formulations were found to 
be similar one another since all the values of f1 were less than 15 and 
the values of f2
 
 were higher than 50. Therefore, this suggested that 
there was no significant difference in the release profile of the 
liquisolid system, however, this also showed the granules prepared 
were able to sustain the PPH release for 8 h with the lowest rate 





Fig. 4: Dissolution profiles of PPH liquisolid granules in the (a) 
simulated gastric fluid and (b) simulated intestinal fluid 
(mean±SD, n=3) 
Table 4: Difference (f1) and similarity (f2
Curve 1 
) factor of each 
dissolution profile of liquisolid formulations 
Curve 2 F1 F2 
F1 F2 4.56 68.91 
F1 F3 2.38 82.04 
F1 F4 9.78 54.00 
F1 F5 5.76 62.74 
F2 F3 4.33 70.28 
F2 F4 5.80 67.23 
F2 F5 4.75 70.84 
F3 F4 8.93 55.43 
F3 F5 6.55 62.24 
F4 F5 9.43 58.73 
 
Drug release kinetics determination 
Based on the dissolution released data, the drug release kinetics of 
each formulation was able to be determined. Each of the dissolution 
plots was fitted to each of release model equation, including zero 
order, first order, Higuchi model, and Hixson-Crowell model. The 
kinetics profile was subsequently able to interpret the release 
mechanism of the formulation. The degree of correlation coefficient 
(r2
The results of this study have shown the feasibility of the preparation 
of PPH liquisolid granules for better sustained release profiles. 
Besides, it has been suggested that the combination of liquid vehicles 
could be utilised to obtain the optimum formulation with the desired 
dissolution profiles. Therefore, following these promising findings, 
further studies such as the formulation of pharmaceutical dosage 
forms using the obtained granules are required to object the clinical 
usage. Furthermore, toxicity and in vivo studies using suitable animal 
models should also be performed to generate a complete review of the 
potential of this proposed system. 
), which was closest to 1, was chosen as the best-fitted to the 
mathematical equation model, as shown in table 3. The results show 
that F1 and F3 were best fitted to first order kinetics. This suggested 
that the drug was transported through non-Fickian diffusion, where 
the release rate depends on the concentration of the drug [30]. This 
model was also followed by the formulation of a water-soluble drug 
in porous matrices [31]. Besides, F1, F4, and F5 were best fitted to 
the Higuchi model. According to Higuchi square root model, the drug 
release of these formulations followed the diffusion controlled 
release mechanism [32].  
 
Table 5: The value of correlation coefficient of each dissolution profile of liquisolid formulation 
Formula Correlation coefficient value (r2) 
Zero order First order Higuchi model Hixson-crowell model 
F1 0.7411 0.9395 0.9234 0.9053 
F2 0.6928 0.8717 0.8937 0.8144 
F3 0.7414 0.9501 0.9219 0.8990 
F4 0.6560 0.7803 0.8652 0.7399 
F5 0.5945 0.7405 0.8282 0.6944 
 
CONCLUSION 
Liquisolid technology is one of the simple and promising methods 
which was successfully adapted to prepare sustained release dosage 
forms. In this study, propranolol hydrochloride (PPH) was selected 
as the drug of choice due to its high-water solubility, low dose, short 
half-life, and frequent dosing. The combination of propylene glycol 
and polysorbate 80 were used as the liquid vehicles. The prepared 
formulations possessed first-order and Higuchi model kinetics. 
There was no significant difference observed in the dissolution 
profile, as all the formulations were able to sustain the drug release 
over 8 h. Therefore, the presented technique can be a promising 
solution for the prolonged release formulation of water-soluble 
drugs. In addition to that, further comprehensive studies are 
considerably required, including the formulation of solid dosage 
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